Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited (BXPHF) Financial Performance & Income Statement Overview
Explore the financials of Botanix Pharmaceuticals Limited (BXPHF), including yearly and quarterly data on income, cash flow, and balance sheets.
Botanix Pharmaceuticals Limited (BXPHF) Income Statement & Financial Overview
Review Botanix Pharmaceuticals Limited BXPHF income statement with detailed quarterly and annual figures.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $377597.00 | $1.69M | $377930.00 | $526976.00 |
| Cost of Revenue | $1.21M | $2.67M | $3.40M | $2.71M |
| Gross Profit | -$831000.00 | -$982000.00 | -$3.02M | -$2.19M |
| Gross Profit Ratio | -$2.20 | -$0.58 | -$8.004 | -$4.15 |
| R&D Expenses | $138077.00 | $834730.00 | $978208.00 | $636670.00 |
| SG&A Expenses | $30.02M | $2.80M | $1.52M | $1.69M |
| Operating Expenses | $30.16M | $7.85M | $2.50M | $2.33M |
| Total Costs & Expenses | $31.37M | $10.52M | $5.90M | $5.04M |
| Interest Income | $0.00 | $34162.00 | $41559.00 | $46946.00 |
| Interest Expense | $0.00 | $4032.00 | $6627.00 | $5064.00 |
| Depreciation & Amortization | $1.12M | $64176.00 | $8431.00 | $93606.00 |
| EBITDA | -$30.85M | -$8.40M | -$5.52M | -$2.25M |
| EBITDA Ratio | -$81.71 | -$4.97 | -$14.60 | -$8.39 |
| Operating Income | -$30.99M | -$8.83M | -$5.53M | -$4.51M |
| Operating Income Ratio | -$82.07 | -$5.22 | -$14.62 | -$8.57 |
| Other Income/Expenses (Net) | $103338.00 | -$1.04M | $59146.00 | -$141828.00 |
| Income Before Tax | -$30.92M | -$9.87M | -$5.47M | -$4.56M |
| Income Before Tax Ratio | -$81.89 | -$5.83 | -$14.47 | -$8.65 |
| Income Tax Expense | -$31924.00 | -$1.47M | $0.00 | $4.00 |
| Net Income | -$30.89M | -$8.40M | -$5.47M | -$4.56M |
| Net Income Ratio | -$81.80 | -$4.97 | -$14.47 | -$8.65 |
| EPS | -$0.02 | -$0.005 | -$0.004 | -$0.004 |
| Diluted EPS | -$0.02 | -$0.005 | -$0.004 | -$0.004 |
| Weighted Avg Shares Outstanding | $1.82B | $1.56B | $1.44B | $1.31B |
| Weighted Avg Shares Outstanding (Diluted) | $1.82B | $1.56B | $1.44B | $1.31B |
The company's financials show resilient growth, with revenue advancing from $526976.00 in Q4 2023 to $377597.00 in Q2 2025. Gross profit remained healthy with margins at -220% in Q2 2025 compared to -415% in Q4 2023. Operating income hit -$30.99M last quarter, sustaining a consistent -8207% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$30.85M. Net income dropped to -$30.89M, while earnings per share reached -$0.02. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan